A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice

Toxicology and Applied Pharmacology

Volumn 147, Issue 1, 1997, Pages 15-30

  Abbas, Richat ^a   Fisher, Jeffrey W ^a  

^a SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; DICHLOROACETIC ACID; GLUCURONIDE; TRICHLOROACETIC ACID; TRICHLOROETHANOL; TRICHLOROETHYLENE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FECES; MALE; METABOLITE; MODEL; MOUSE; NONHUMAN; PARTITION COEFFICIENT; PHARMACOKINETICS; TOXICOKINETICS; URINARY EXCRETION; XENOBIOTIC METABOLISM;

ANIMALIA; ZEA MAYS;

EID: 0030694692     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8190     Document Type: Article

References (59)

1. Abbas R., Seckel C. S., Creech J. R., Garrity B. L., Black R. K., Byczkowski J. Z., Fisher J. W. A physiologically based pharmacokinetic model to describe disposition of chloral hydrate and trichloroethanol in mice. Int. Toxicol. 33:1995;P-20.
2. Abbas R., Seckel C. S., MacMahon K. L., Fisher J. W. Determination of kinetic rate constants for chloral hydrate, trichloroethanol, trichloroacetic acid and dichloroacetic acid: A physiologically based modeling approach. Toxicologist. 36:1997;32-33.
3. Allen B. C., Fisher J. W. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal. 13:1993;71-86.
4. Andersen M. E., Gargas M. L., Clewell H. J. III, Severyn K. M. Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylenein vivo. Toxicol. Appl. Pharmacol. 89:1987;149.
5. Bogen K. T. Pharmacokinetics for regulatory risk analysis: The case of trichloroethylene. Regul. Toxicol. Pharmacol. 8:1988;447-466.
6. Breimer D., Ketelaar H. C. J., Van Rossum J. M. Gas chromatographic determination of chloral hydrate, trichloroethanol, trichloroacetic acid in blood and urine employing head-space analysis. J. Chromatogr. 88:1974;55-63.
7. Bruckner J. V., Davis B. D., Blancato J. N. Metabolism, toxicity, and carcinogenicity of trichloroethylene. Toxicology. 20:1989;31-50.
8. Buben J. A., O'Flaherty E. J. Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: A dose-effect study. Toxicol. Appl. Pharmacol. 78:1985;105-122.
9. Bull R. J., Sanchez I. M., Nelson M. A., Larson J. L., Lansing A. J. Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate. Toxicology. 63:1990;341-359.
10. Clewell H. J. III, Gentry P. R., Gearhart J. M., Allen B. C., Andersen M. E. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: Examples with vinyl chloride and trichloroethylene. Chemosphere. 1996.
11. Curry S. H., Lorenz A., Chu P. I., Limacher M., Stacpoole P. W. Disposition and pharmacokinetics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm. Drug Dispos. 12:1991;375-390.
12. Dallas C. E., Gallo J. M., Ramanathan R., Muralidhara S., Bruckner J. V. Physiological pharmacokinetic modeling of inhaled trichloroethylene in rats. Toxicol. Appl. Pharmacol. 110:1991;303.
13. Daniel F. B., Stober J. A., Olson G. R., Pages N. P. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetylaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam. Appl. Toxicol. 19:1992;159-168.
14. Davidson I. W. F., Beliles R. P. Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics. Drug Metab. Rev. 23:1991;493-599.
15. DeAngelo A. B., Daniel F. B., Stober J. A., Olson G. R. The carcinogenicity of dichloroacetic acid in the male B6C3F1 mouse. Fundam. Appl. Toxicol. 16:1991;337-347.
16. Dekant W., Metzler M., Henschler D. Novel metabolism of trichloroethylene through dechlorination reactions in rats, mice and humans. Biochem. Pharmcol. 33:1984;2021-2027.
17. Dekant W., Schulz M., Metzler M., Henschler D. Absorption, elimination and metabolism of trichloroethylene: A quantitative difference between rats and mice. Xenobiotica. 16:1986;143-150.
18. Droz P. O., Wu M. M., Cumberland W. G., Berode M. Variability in biological monitoring of solvent exposure. I. Development of a population physiological model. Br. J. Ind. Med. 46:1989a;447-460.
19. Droz P. O., Wu M. M., Cumberland W. G. Variability in biological monitoring of solvent exposure. II. Application of a population physiological model. Br. J. Ind. Med. 46:1989b;547-558.
20. Fisher J. W., Allen B. C. Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal. 13:1993;87-95.
21. Fisher J. W., Andersen M. E. Using inhalation kinetic data in route-to-route extrapolation: A physiological model for oral absorption of trichloroethylene. In Principles of Route-to-Route Extrapolation for Risk Assessment. 1990;Elsevier Science, New York. p. 297-.
22. Fisher J. W., Whittaker T. A., Taylor D. H., Clewell H. J. III, Andersen M. E. Physiologically based pharmacokinetic modeling of the pregnant rat: A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol. Appl. Pharmacol. 99:1989;395-414.
23. Fisher J. W., Whittaker T. A., Taylor D. H., Clewell H. J. III, Andersen M. E. Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol. Appl. Pharmacol. 102:1990;497-513.
24. Fisher J. W., Gargas M. L., Allen B. C., Andersen M. E. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol. Appl. Pharmacol. 109:1991;183-195.
25. Fukuda K., Takemoto K., Tsuruta. Inhalation carcinogenicity of trichloroethylene in mice and rats. Ind. Health. 21:1983;243-254.
26. Gargas M. L., Burgess R. J., Voisard D. E., Cason G. H., Andersen M. E. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98:1989;87-99.
27. Gibaldi M., Perrier D. Pharmacokinetics. 1982;Marcel Dekker, New York/Basel.
28. Green T., Prout M. S. Species differences in response to trichloroethylene. II. Biotransformation in rats and mice. Toxicol. Appl. Pharmacol. 79:1985;401-411.
29. Henschler D. Metabolism and mutagenicity of halogenated olefins: A comparison of structure and activity. Environ. Health Perspect. 21:1977;61-64.
30. Herren-Freund S. L., Pereira M. A., Khoury M. D., Olson G. The carcinogenicity of trichloroethylene and its metabolites trichloroacetic acid and dichloroacetic acid, in mouse liver. Toxicol. Appl. Pharmacol. 90:1987;183-189.
31. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 1982;IARC, Lyon. p. 247-249.
32. International Life Science Institute, Risk Science Institute, 1994, Physiological Parameter Values for PBPK Models.
33. Jepson G. W., Hoover, Black R K., McCafferty J. D., Mahle D. A., Gearhart J. M. A partition coefficient method for non-volatile and intermediate volatility chemicals in biological tissues. Fund. Appl. Tox. 22:1994;519-524.
34. Ketcha M. M., Warren D. A., Bishop C. T., Brashear W. T. Factors influencing the conversion of trichloroacetic acid to dichloroacetic acid in biological matrices. J. Anal. Toxicol. 20:1996;236-241.
35. Kim H. J., Bruckner J. V., Dallas C. E., Gallo J. M. Effect of dosing vehicles on the pharmacokinetics of orally administered carbon tetrachloride in rats. Toxicol. Appl. Pharmacol. 102:1990;50-60.
36. Koizumi A. Potential of physiologically based pharmacokinetics to amalgamate kinetic data of trichloroethylene and tetrachloroethylene obtained in rats and man. Br. J. Ind. Med. 46:1989;239-249.
37. Larson J. L., Bull R. J. Metabolism and lipoperoxidation activity of trichloroacetate and dichloroacetate in rats and mice. Toxicol. Appl. Pharmacol. 115:1992;268-277.
38. Lipscomb J. C., Garrett C. M., Mahle D. A. Comparison of thein vitro. Toxicologist. 30:1996;318.
39. Mahle D. A., McCafferty J. D., Frazier J. M., Barton H. A. Tissue distribution of trichloroacetate in B6C3F1 mice and fisher 344 rats. Toxicol. Appl. Pharmacol. Suppl. 30:1996;33.
40. Maltoni C., Lefemine G., Cotti G. Archives of Research on Industrial Carcinogenesis: Experimental Research on Trichloroethylene Carcinogenesis. 1986a;Princeton Scientific, Princeton.
41. Maltoni C., Lefemine G., Cotti G., Perino G. Long-term carcinogenicity bioassays on trichloroethylene administered by inhalation to Sprague-Dawley rats and Swiss and B6C3F1 mice. Ann. NY Acad. Sci. 534:1986b;316-342.
42. Muller G., Spassovski M., Henschler D. Trichloroethylene exposure and trichloroethylene metabolites in urine and blood. Arch. Toxicol. 29:1972;335-340.
43. Muller G., Spassovski M., Henschler D. Metabolism of trichloroethylene in man. II. Pharmacokinetics of the metabolites. Arch. Toxicol. 32:1974;283-295.
44. Muller G., Spassovski M., Henschler D. Metabolism of trichloroethylene in man. III. Interaction of trichloroethylene and ethanol. Arch. Toxicol. 33:1975;173-189.
45. National Cancer Institute, 1976, Carcinogenesis Bioassay of Trichloroethylene.
46. National Institute of Occupational Safety and Health, 1978, Special Occupational Hazard Review of Trichloroethylene, Priorities and Research Analysis Branch, Rockville, MD.
47. National Toxicology Program, 1982, Carcinogenesis Bioassay of Trichloroethylene.
48. National Toxicology Program, 1988, Toxicology and Carcinogenesis Studies of Trichloroethylene in 4 Strains of Rats (ACI, August, Marshall, Osborne-Mendel) (Gavage Studies).
49. National Toxicology Program, 1990, Carcinogenesis Studies of Trichloroethylene (without Epichlorohydrin) in F344/N Rats and in B6C3F1 Mice (Gavage Studies), U.S. Department of Health, Education, Welfare, National Institutes of Health, Bethesda, MD.
50. Odum J., Foster J. R., Green T. A mechanism for the development of Clara cell lesions in the mouse lung after exposure to trichloroethylene. Chem.-Biol. Interact. 83:1992;135-153.
51. Opdam J. J. G. Intra- and interindividual variability in the kinetics of a poorly and highly metabolizing solvent. Br. J. Ind. Med. 46:1989;831-845.
52. Opdam J. J. G., Smolders J. F. J. A method for the retrospective estimation of the individual respiratory intake of a highly and a poorly metabolizing solvent during rest and physical exercise. Br. J. Ind. Med. 46:1989;250-260.
53. Seckel C. S., Creech J. R., Garrity B. L., Black R. K., Byczkowski J. Z. Tissue solubility and kinetics for metabolites of trichloroethylene-chloral hydrate and trichloroethanol. Toxicologist. 15:1995;198.
54. Srivatsan V., Varkonyi P., Muralidhara S., Dallas C. E., Gallo J. M., Bruckner J. V. Physiologically based pharmacokinetic (PBPK) modeling of the tissue deposition of inhaled 1,1,2-trichloroethylene (TCE). Toxicologist. 13:1993;357.
55. Staats D. A., Fisher J. W., Connolly R. B. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models: A two-compartment description. Drug Metab. Dispos. 19:1991;144-148.
56. Templin M. V., Parker J. C., Bull R. J. Relative formation of dichloroacetate and trichloroacetate from trichloroethylene in male B6C3F1 mice. Toxicol. Appl. Pharmacol. 123:1993;1-8.
57. Templin M. V., Stevens D. K., Stenner R. D., Bonate P. L., Tuman D., Bull R. J. Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J. Toxicol. Environ. Health. 44:1995;435-447.
58. USEPA (U.S. Environmental Protection Agency), 1985, Health Assessment Document for Trichloroethylene, Environmental Criteria and Assessment office, U.S. Environmental Protection Agency, Research Triangle Park, NC.
59. Vinegar A., Williams R. J., Fisher J. W., McDougal J. N. Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: A physiologically based pharmacokinetic model in the male Fischer 344 rat. Toxicol. Appl. Pharmacol. 129:1994;102-113.